

Market Announcement

23 September 2026

Paradigm Biopharmaceuticals Limited (ASX: PAR) – Suspension from Quotation

The securities of Paradigm Biopharmaceuticals Limited ('PAR') will be suspended from quotation immediately under Listing Rule 17.2 at the request of PAR, pending the release of an announcement by PAR.

Unless ASX decides otherwise, the securities will remain suspended until the earlier of:

- the end of the period stated in PAR's request for voluntary suspension; or
- the release of the announcement to the market.

PAR's request for voluntary suspension is attached below for the information of the market.

Issued by

ASX Compliance

23 September 2026

By email: melissa.kostopoulos@asx.com.au

Melissa Kostopoulos
Senior Adviser, Listings Compliance (Melbourne)
ASX Limited

Dear Melissa

Request for Voluntary Suspension

Paradigm Biopharmaceuticals Limited (ACN 169 346 963) (the **Company**), requests a voluntary suspension of its quoted securities (ASX Codes: **PAR and PAROB**) from the commencement of trading on Wednesday, 23 September 2026, in accordance with ASX Listing Rule 17.2.

In accordance with ASX Listing Rule 17.2, the Company provides the following information:

1. The Company is seeking the voluntary suspension pending an announcement by the Company to the market in relation to the outcome of the interim analysis for its PARA_OA_012 Phase 3 trial (**IA Results**). The voluntary suspension is requested to assist the Company in managing its continuous disclosure obligations pending release of that announcement.
2. The Company requests that the voluntary suspension remain in place until the announcement regarding the IA Results is released to the market, or commencement of trading on Monday 28th September subject to ASX's agreement to reinstatement of the Company's securities to quotation.
3. The Company is not aware of any reason why the voluntary suspension should not be granted or of any other information necessary to inform the market about the voluntary suspension.

Please contact me if you require any further information concerning this matter.

Yours sincerely



Abby Macnish Niven
Company Secretary
For and on behalf of the Board of Paradigm Biopharmaceuticals Limited